

Dr. MARIA JOSE PINZON GARCIA
RED COLOMBIANA DE MEDICINA GENETICA SAS - PREGEN
BOGOTA
CARRERA 15 A # 106 - 42
11001 BOGOTA
Colombia

Date of Report 26.06.2026
Sample Received 16.06.2026
Date of Sampling 06.06.2026
LAB-ID 262026298

Medical Report

Patient name	HEREDIA MARQUEZ HALLY	Sample-ID	A0358637
Date of Birth	23.03.2026	Gender	F

Indication: Newborn Screening

Method(s): Immunoassay, Tandem mass spectrometry from Dried Blood Spot. qPCR from Dried Blood Spot.

Results:

Parameter	Value	Unit	Reference
Birth weight (g)	3100	g	-
17-hydroxyprogesterone (17OHP)	<5.0	nmol/L	< 90.0
Thyroid-stimulating hormone (TSH)	2.1	µU/mL	< 15.0
Biotinidase	123.0	U	> 51.0
Galactose-1-P-uridyltransferase (GALT)	7.6	U/g Hb	> 2.5
Immunoreactive trypsinogen (IRT)	<15	ng/mL	< 65.0
Phenylalanine	29.6	µmol/L	< 150.0
Amino acid profile	negative		-
Acylcarnitine profile	negative		-

Interpretation: NEGATIVE RESULT

Patient name	HEREDIA MARQUEZ HALLY
Date of Birth	23.03.2026

Sample-ID	A0358637
Gender	F

Results:

Amino Acids

Parameter	Value	Unit	Reference
Phenylalanine (Phe)	29.6	µmol/L	< 150.0
Phenylalanine / Tyrosine ratio (Phe/Tyr)	0.28	µmol/L	< 2.20
Tyrosine (Tyr)	105.0	µmol/L	< 200.0
Leucine (Leu)	125.9	µmol/L	< 270.0
Valine (Val)	50.0	µmol/L	< 200.0
Methionine (MET)	24.0	µmol/L	< 78.0
Methionine / Phenylalanine (Met/Phe)	0.81	µmol/L	< 1.60
Citrulline (Cit)	14.5	µmol/L	< 50.0
Ornithine (Orn)	119.7	µmol/L	< 250.0
Ornithine / Citrulline ratio (Orn/Cit)	8.26	µmol/L	1.50 - 20.00
Proline (Pro)	130.9	µmol/L	< 350.0
Alanine (Ala)	263.3	µmol/L	< 750.0
Arginine (Arg)	13.7	µmol/L	< 100.0
Aspartic acid (Asp)	51.0	µmol/L	< 100.0
Glutamic acid (Glu)	216.8	µmol/L	< 600.0
Glycamine (Gly)	153.4	µmol/L	< 700.0

Acylcarnitines

Free carnitine (C0)	36.36	µmol/L	6.00 - 100.00
acetylcarnitine (C2)	13.19	µmol/L	1.34 - 48.81
propionylcarnitine (C3)	1.23	µmol/L	0.13 - 6.60
butyryl-/isobutyrylcarnitine (C4)	0.06	µmol/L	0.03 - 0.90
isovaleryl-/2-methylbutyrylcarnitine(C5)	0.06	µmol/L	0.02 - 2.00
tiglylcarnitine (C5:1)	0.01	µmol/L	< 0.20
hydroxyvalerylcarnitine (C5OH)	0.22	µmol/L	0.02 - 0.57
glutarylacarnitine (C5DC)	0.04	µmol/L	< 0.30
hexanoylcarnitine (C6)	0.04	µmol/L	0.01 - 0.13
octanoylcarnitine (C8)	0.02	µmol/L	0.01 - 0.30
decanoylcarnitine (C10)	0.04	µmol/L	0.01 - 0.36
decenoylcarnitine (C10:1)	0.07	µmol/L	< 0.30
dodecanoylcarnitine (C12)	0.07	µmol/L	0.10 - 0.60
myristoylcarnitine (C14)	0.23	µmol/L	0.01 - 0.57
tetradecenoylcarnitine (C14:1)	0.13	µmol/L	0.10 - 0.43
palmitoylcarnitine (C16)	1.65	µmol/L	0.62 - 7.81
3-hydroxypalmitoylcarnitine (C16OH)	0.03	µmol/L	< 0.10
stearoylcarnitine (C18)	0.92	µmol/L	0.30 - 2.40
oleylcarnitine (C18:1)	5.24	µmol/L	0.06 - 3.86
3-hydroxystearoylcarnitine (C18OH)	0.01	µmol/L	< 0.09
malonylcarnitine (C3DC)	0.07	µmol/L	< 0.50

Amino acid levels are indicators of phenylketonuria, tyrosinemia, MSUD, hydroxyprolinuria, hypermethioninemia (homocystinuria), citrullinemia, argininosuccinate aziduria, hyperargininemia, and hyperprolinemia. Acylcarnitine levels are indicators of carnitine uptake disorders, CPT-I deficiency, CPT-II deficiency, CAT deficiency, propionaciduria, methylmalonic aciduria, malonic aciduria, SCAD deficiency/ethylmalonic aciduria, isovaleric aciduria, HMG-CoA lyase deficiency, 3-methylcrotonyl-CoA carboxylase deficiency, methylglutaconiduria, MCAD deficiency, VLCAD deficiency, LCHAD deficiency, glutaraziduria I, multiple acyl-CoA dehydrogenase deficiency (MAD deficiency/glutaraziduria II), and Beta-ketothiolase deficiency.

Please note: Inconspicuous negative biochemical results cannot exclude any inborn error of metabolism or endocrine disorder with certainty in newborns. We recommend any follow-up or genetic testing if any clinical symptoms are present.

Authorized By: Assoc.-Prof. Dr. Andrea-Romana KASPER, MD, PhD
[Specialist for Pediatrics, Neonatology and Nutrition]

Report was electronically signed and approved.

Contact Details
Assoc.-Prof. Dr. Andrea-Romana KASPER, MD, PhD
E-Mail: info@archimedlife.com

ARCHIMEDlife GmbH
International Medical Laboratory+
Leberstrasse 20/2 | 1110 Vienna, Austria
www.archimedlife.com